Kombinacija HMG-CoA reduktaznega inhibitorja rosuvastatina s fosfodiesteraznim 4 inhibitorjem, kot je roflumilast, roflumilast-N-oksid, za zdravljenje vnetnih pljučnih bolezni

• 收藏
• 分享

专利权人:

TAKEDA GMBH

发明人:

WOLLIN STEFAN-LUTZ,WOHLSEN ANDREA,BRAUN CLEMENS,MARX DEGENHARD,Wollin Stefan-Lutz,Wohlsen Andrea,Braun Clemens,Marx Degenhard

申请号：

SI200731395

公开号：

SI2359826T1

申请日:

2007.07.03

申请国别(地区):

SI

年份:

2014

代理人:

摘要：

The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the preventive and curative treatment of an inflammatory pulmonary disease, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/